OncoAssure and Diacarta Collaborate to Develop Prostate Cancer Test

Diacarta and OncoAssure have unveiled a partnership to develop a prostate cancer diagnostic tool. 

The partnership seeks to bring to market OncoAssure’s prostate cancer test, specifically developed to assist in identifying patients with a reduced risk of recurrence after undergoing treatment. 

The collaboration will leverage DiaCarta’s proficiency in clinical diagnostic solutions to finalise the validation of the OncoAssure Prostate diagnostic tool. 

Des O’Leary, the head executive at OncoAssure, stated, “DiaCarta has established a high-quality CAP/CLIA laboratory for LDT testing in California.” 

O’Leary went on to add, “This partnership will expedite the validation process and pave the way for commercialisation of the OncoAssure Prostate LDT test, benefitting healthcare providers and patients alike.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.